Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications

RECOMMENDED

Further Publications

Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP

doi: 10.1016/j.chest.2021.02.032

RECOMMENDED

Further Publications

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H

doi: 10.1016/j.chest.2020.11.027

RECOMMENDED

Lung Cancer

Management of pulmonary toxicity associated with immune checkpoint inhibitors

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Eur Respir Rev.

Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J

doi: 10.1183/16000617.0012-2019.

RECOMMENDED

Lung CancerPleural DiseasesFurther Publications

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Chest.

Suresh K, Naidoo J, Lin CT, Danoff S

doi: 10.1016/

RECOMMENDED

Lung Cancer

Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Andreano A, Bergamaschi W, Russo AG

doi: 10.1016/j.lungcan.2021.06.019

RECOMMENDED

COPDEmphysema

The relationship between body mass index and health-related quality of life in COPD: real-world evidence based on claims and survey data

★ 2 Recommended by Dr Martin Frey, Faculty Member

Respir Res.

Huber MB, Kurz C, Kirsch F, Schwarzkopf L, Schramm A, Leidl R

doi: 10.1186/s12931-020-01556-0.Visit the original publication at ncbi.nlm.nih.gov

RECOMMENDED

Lung Cancer

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Clin Lung Cancer.

Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K

doi: 10.1016/j.cllc.2020.06.010.

RECOMMENDED

Further Publications

Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Wechsler ME, Peters SP, Hill TD, Ariely R, DePietro MR, Driessen MT, Terasawa EL, Thomason DR, Panettieri RA Jr

doi: 10.1016/j.chest.2020.11.060

RECOMMENDED

Asthma

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

★ 3 Recommended by Dr Martin Frey, Faculty Member

Chest.

Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ

doi: 10.1016/j.chest.2020.08.2083.

Related content

Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

Management of pulmonary toxicity associated with immune checkpoint inhibitors

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort

The relationship between body mass index and health-related quality of life in COPD: real-world evidence based on claims and survey data

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma